AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 8176574 — intervention group
Group type: EXPERIMENTAL
Intervention: Clarithromycin suspension at 15 mg/kg per dose every 12 hours
Number of subjects: 25
Study 8176574 — intervention group
Group type: EXPERIMENTAL
Intervention: Clarithromycin suspension
Number of subjects: 25
Study 3653081 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl 1, 2 or 3 micrograms kg‐1 in adults
Number of subjects: 190
Study 3653081 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl 1 or 2 micrograms kg‐1 in children
Number of subjects: 190
Study 3653081 — intervention group
Group type: COMPARATOR
Intervention: Control group (no pretreatment) in adults
Number of subjects: 190
Study 3653081 — intervention group
Group type: COMPARATOR
Intervention: Control group (no pretreatment) in children
Number of subjects: 190
Study 3653081 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl (any dose)
Number of subjects: 190
Study 28843973 — intervention group
Group type: EXPERIMENTAL
Intervention: Carrot soup with MSG (5 g, 1% w/w)
Number of subjects: 43
Study 28843973 — intervention group
Group type: EXPERIMENTAL
Intervention: Whey protein enriched carrot soup with MSG (5 g, 1% w/w)
Number of subjects: 43
Study 28843973 — intervention group
Group type: EXPERIMENTAL
Intervention: Carrot soup with MSG and protein
Number of subjects: 43
Study 28843973 — intervention group
Group type: COMPARATOR
Intervention: Carrot soup with no additions
Number of subjects: 43
Study 26961571 — intervention group
Group type: EXPERIMENTAL
Intervention: Furosemide
Number of subjects: 67
Study 26961571 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethacrynic acid
Number of subjects: 67
Study 26961571 — intervention group
Group type: EXPERIMENTAL
Intervention: Cross-clamp time
Number of subjects: 67
Study 26961571 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood pH at the end of POD0
Number of subjects: 67
Study 25104273 — intervention group
Group type: EXPERIMENTAL
Intervention: eicosapentaenoic acid-docosahexaenoic acid
Number of subjects: 2344
Study 25104273 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 2344
Study 25104273 — intervention group
Group type: EXPERIMENTAL
Intervention: α-linolenic acid
Number of subjects: 2344
Study 25104273 — intervention group
Group type: EXPERIMENTAL
Intervention: eicosapentaenoic acid-docosahexaenoic acid plus α-linolenic acid
Number of subjects: 2344
Study 22808789 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteral nutritive mixtures with branched-chain amino acids (BCAA)
Number of subjects: 0
Study 20174466 — intervention group
Group type: EXPERIMENTAL
Intervention: NSAIDs
Number of subjects: 315
Study 20174466 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (ASA) alone
Number of subjects: 315
Study 20174466 — intervention group
Group type: COMPARATOR
Intervention: NSAIDs plus ASA
Number of subjects: 315
Study 17851077 — intervention group
Group type: EXPERIMENTAL
Intervention: Concomitant tumour bed boost (CB) with whole breast radiotherapy (RT) delivering 50Gy and an electron boost of 12.5Gy in 5 weekly fractions.
Number of subjects: 30
Study 17851077 — intervention group
Group type: COMPARATOR
Intervention: Conventional radiotherapy (CRT) with tumour bed boost of 15Gy in 6 fractions delivered after whole breast irradiation.
Number of subjects: 30
Study 17851077 — intervention group
Group type: COMPARATOR
Intervention: Concomitant tumour bed boost (CB) with whole breast RT compared to CRT.
Number of subjects: 30
Study 16375760 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking Program (WP) and Vitamin Supplements
Number of subjects: 0
Study 16375760 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking Program (WP) and Placebo Supplements
Number of subjects: 0
Study 16375760 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo Activity Program (PAP) and Vitamin Supplements
Number of subjects: 0
Study 16375760 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo Activity Program (PAP) and Placebo Supplements
Number of subjects: 0
Study 12452877 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral antifungal agents
Number of subjects: 496
Study 10632026 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% chloroprocaine (20 microl)
Number of subjects: 10
Study 10632026 — intervention group
Group type: COMPARATOR
Intervention: Saline (20 microl)
Number of subjects: 10
Study 7769406 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma fibrinogen levels
Number of subjects: 6457
Study 7769406 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivariable linear regression analysis
Number of subjects: 6457
Study 2022788 — intervention group
Group type: EXPERIMENTAL
Intervention: In-office bleaching technique
Number of subjects: 20
Study 2022788 — intervention group
Group type: COMPARATOR
Intervention: Control group (no bleaching)
Number of subjects: 20
Study 6114845 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydroergotamine (2 mg)
Number of subjects: 51
Study 6114845 — intervention group
Group type: EXPERIMENTAL
Intervention: Etilefrine (20 mg)
Number of subjects: 51
Study 6114845 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment (2 mg dihydroergotamine and 20 mg etilefrine)
Number of subjects: 51
Study 6114845 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study 31025365 — intervention group
Group type: EXPERIMENTAL
Intervention: Platform-Switching (PS) components
Number of subjects: 68
Study 31025365 — intervention group
Group type: COMPARATOR
Intervention: Platform-Matching (PM) components
Number of subjects: 68
Study 31025365 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (PS and PM)
Number of subjects: 68
Study 29358870 — intervention group
Group type: EXPERIMENTAL
Intervention: Study regimen (oral sulfate solution 89 mL with diatrizoate solution: boost 1 = 60 mL, boost 2 = 30 mL)
Number of subjects: 0
Study 29358870 — intervention group
Group type: COMPARATOR
Intervention: Control regimen (oral sulfate solution 89 mL)
Number of subjects: 0
Study 29358870 — intervention group
Group type: EXPERIMENTAL
Intervention: Study regimen
Number of subjects: 0
Study 29358870 — intervention group
Group type: COMPARATOR
Intervention: Control regimen
Number of subjects: 0
Study 25605861 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy plus trastuzumab (arms B and C)
Number of subjects: 1282
Study 25605861 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy alone (arm A)
Number of subjects: 1282
Study 24854634 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal bilateral primary somatosensory areas transcranial direct current stimulation
Number of subjects: 10
Study 24854634 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 10
Study 22961225 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term high-fat overfeeding (HFO) diet
Number of subjects: 21
Study 22961225 — intervention group
Group type: COMPARATOR
Intervention: Control diet
Number of subjects: 21
Study 19399720 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH antagonists
Number of subjects: 0
Study 19399720 — intervention group
Group type: COMPARATOR
Intervention: LHRH agonists
Number of subjects: 0
Study 17624483 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise programme provided by public health nurses, comprising a weekly exercise class of 2 hours for 17 weeks, supplemented by daily home exercises
Number of subjects: 268
Study 17624483 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 268
Study 15112866 — intervention group
Group type: EXPERIMENTAL
Intervention: ReN1869 25 mg
Number of subjects: 21
Study 15112866 — intervention group
Group type: EXPERIMENTAL
Intervention: ReN1869 50 mg
Number of subjects: 21
Study 15112866 — intervention group
Group type: EXPERIMENTAL
Intervention: ReN1869 (subchronic mode, one week treatment)
Number of subjects: 21
Study 15112866 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 11532537 — intervention group
Group type: EXPERIMENTAL
Intervention: Infrathreshold stimulation
Number of subjects: 23
Study 11532537 — intervention group
Group type: COMPARATOR
Intervention: Placebo stimulation
Number of subjects: 23
Study 11532537 — intervention group
Group type: EXPERIMENTAL
Intervention: Suprathreshold stimulation
Number of subjects: 23
Study 11532537 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 Hz stimulation
Number of subjects: 23
Study 11532537 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 Hz stimulation
Number of subjects: 23
Study 9510448 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Number of subjects: 8
Study 8293847 — intervention group
Group type: EXPERIMENTAL
Intervention: Levonorgestrel-releasing IUD
Number of subjects: 0
Study 8293847 — intervention group
Group type: COMPARATOR
Intervention: Copper TCu 380Ag IUD
Number of subjects: 0
Study 2735337 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucralfate (1 g four times per day)
Number of subjects: 16
Study 2735337 — intervention group
Group type: COMPARATOR
Intervention: Placebo (one tablet four times per day)
Number of subjects: 16
Study 2735337 — intervention group
Group type: COMPARATOR
Intervention: Ranitidine (150 mg three times per day)
Number of subjects: 16
Study 2735337 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucralfate (1 g four times per day) plus Ranitidine (150 mg three times per day)
Number of subjects: 16
Study 2735337 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus Ranitidine (150 mg three times per day)
Number of subjects: 16
Study 29023359 — intervention group
Group type: EXPERIMENTAL
Intervention: Low EA (23.4-34.1 kcal·kg ffm·d), n = 11
Number of subjects: 35
Study 29023359 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate EA (34.9-40.7 kcal·kg ffm·d), n = 12
Number of subjects: 35
Study 29023359 — intervention group
Group type: EXPERIMENTAL
Intervention: High EA (41.2-50.1 kcal·kg ffm·d), n = 12
Number of subjects: 35
Study 29023359 — intervention group
Group type: EXPERIMENTAL
Intervention: Generalized linear mixed-effects model
Number of subjects: 35
Study 27398697 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive Behavior Education Program (IBEP)
Number of subjects: 101
Study 27398697 — intervention group
Group type: COMPARATOR
Intervention: Routine GDM management
Number of subjects: 101
Study 24715602 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal progesterone (VP) 8% gel
Number of subjects: 459
Study 24715602 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 459
Study 22978357 — intervention group
Group type: EXPERIMENTAL
Intervention: Working memory training (Cogmed RM)
Number of subjects: 60
Study 22978357 — intervention group
Group type: COMPARATOR
Intervention: Math training (Academy of Math)
Number of subjects: 60
Study 20521327 — intervention group
Group type: EXPERIMENTAL
Intervention: d-amphetamine
Number of subjects: 32
Study 20521327 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 32
Study 18288528 — intervention group
Group type: EXPERIMENTAL
Intervention: Flank approach (group A)
Number of subjects: 50
Study 18288528 — intervention group
Group type: COMPARATOR
Intervention: Sub-mesocolic approach (group B)
Number of subjects: 50
Study 15066608 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fiber (13.5 g/d) wheat bran fiber cereal supplement
Number of subjects: 685
Study 15066608 — intervention group
Group type: COMPARATOR
Intervention: Low-fiber (2.0 g/d) wheat bran fiber cereal supplement
Number of subjects: 685
Study 15066608 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatment groups combined
Number of subjects: 685
Study 11495405 — intervention group
Group type: EXPERIMENTAL
Intervention: Buffered lidocaine with epinephrine solution
Number of subjects: 30
Study 11495405 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination buffered lidocaine with epinephrine plus hyaluronidase solution
Number of subjects: 30
Study 9727279 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytokine levels in asthmatics (IL-6, TNF-alpha)
Number of subjects: 32
Study 9727279 — intervention group
Group type: COMPARATOR
Intervention: Cytokine levels in controls (IL-6, TNF-alpha)
Number of subjects: 32
Study 9727279 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-gamma levels in both groups
Number of subjects: 32
Study 7983113 — intervention group
Group type: EXPERIMENTAL
Intervention: Internal fixation
Number of subjects: 3
Study 7983113 — intervention group
Group type: COMPARATOR
Intervention: Hemiarthroplasty
Number of subjects: 3
Study 2648144 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid mouthwash (10 ml of a 4.8 percent aqueous solution)
Number of subjects: 39
Study 2648144 — intervention group
Group type: COMPARATOR
Intervention: Placebo mouthwash
Number of subjects: 39
Study 31570881 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted therapies
Number of subjects: 215
Study 31570881 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunotherapy
Number of subjects: 215
Study 31570881 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab
Number of subjects: 215
Study 31570881 — intervention group
Group type: EXPERIMENTAL
Intervention: Colorectal cancer immunotherapy
Number of subjects: 215
Study 28320421 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual care and patient education (7 individual sessions focusing on pain behavior and pain coping managed by a physiotherapist)
Number of subjects: 56
Study 28320421 — intervention group
Group type: COMPARATOR
Intervention: Usual care (operation and standard rehabilitation)
Number of subjects: 56
Study 26162244 — intervention group
Group type: EXPERIMENTAL
Intervention: Canadian Diabetes Risk Assessment Questionnaire (CANRISK) in women <40 years old
Number of subjects: 74
Study 26162244 — intervention group
Group type: EXPERIMENTAL
Intervention: Canadian Diabetes Risk Assessment Questionnaire (CANRISK) in women >40 years old
Number of subjects: 74
Study 23254274 — intervention group
Group type: EXPERIMENTAL
Intervention: R+A training
Number of subjects: 72
Study 23254274 — intervention group
Group type: EXPERIMENTAL
Intervention: WBV training
Number of subjects: 72
Study 23254274 — intervention group
Group type: COMPARATOR
Intervention: Control (CON) group
Number of subjects: 72
Study 21616946 — intervention group
Group type: EXPERIMENTAL
Intervention: Acamprosate (2 g/day)
Number of subjects: 56
Study 21616946 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study 21616946 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups combined
Number of subjects: 56
Study 19793858 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Protein (HP) diet
Number of subjects: 180
Study 19793858 — intervention group
Group type: COMPARATOR
Intervention: High-Carbohydrate (HC) diet
Number of subjects: 180
Study 17046117 — intervention group
Group type: EXPERIMENTAL
Intervention: Altissimi and Mancini technique
Number of subjects: 20
Study 17046117 — intervention group
Group type: COMPARATOR
Intervention: Gale technique
Number of subjects: 20
Study 12723677 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental group (received instruction on lower limb position and auditory cues)
Number of subjects: 61
Study 12723677 — intervention group
Group type: COMPARATOR
Intervention: Control group (received no instruction)
Number of subjects: 61
Study 10792154 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled-release oxybutynin tablets (10 mg once daily)
Number of subjects: 130
Study 10792154 — intervention group
Group type: COMPARATOR
Intervention: Conventional oxybutynin tablets (5 mg twice daily)
Number of subjects: 130
Study 9054629 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 x RDI VITE supplement (provided in cereal)
Number of subjects: 60
Study 9054629 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 x RDI VITE supplement (provided in capsules)
Number of subjects: 60
Study 9054629 — intervention group
Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 60
Study 9054629 — intervention group
Group type: EXPERIMENTAL
Intervention: VITE-supplemented group
Number of subjects: 60
Study 8311570 — intervention group
Group type: EXPERIMENTAL
Intervention: Single oral 6 mg/kg dose of DEC
Number of subjects: 50
Study 8311570 — intervention group
Group type: EXPERIMENTAL
Intervention: Single oral 6 mg/kg dose of DEC preceded by 1 mg/kg DEC primer
Number of subjects: 50
Study 8311570 — intervention group
Group type: EXPERIMENTAL
Intervention: Single oral 220 micrograms/kg dose of ivermectin
Number of subjects: 50
Study 8311570 — intervention group
Group type: EXPERIMENTAL
Intervention: Single oral 200 micrograms/kg dose of ivermectin preceded by a 20 micrograms/kg ivermectin primer
Number of subjects: 50
Study 8311570 — intervention group
Group type: EXPERIMENTAL
Intervention: Single oral 400 micrograms/kg dose of ivermectin preceded by a 20 micrograms/kg ivermectin primer
Number of subjects: 50
Study 3085896 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 g elemental calcium plus 400 U Vitamin D
Number of subjects: 31
Study 3085896 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study 31999839 — intervention group
Group type: EXPERIMENTAL
Intervention: Dasatinib 100 mg daily
Number of subjects: 149
Study 29032638 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofogliflozin
Number of subjects: 0
Study 29032638 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 26951136 — intervention group
Group type: COMPARATOR
Intervention: Ciprofloxacin 500 mg bid per os for 3 days starting the day before biopsy
Number of subjects: 110
Study 26951136 — intervention group
Group type: EXPERIMENTAL
Intervention: Meropenem 1 g intravenously 1 hour prior to the procedure
Number of subjects: 110
Study 24681657 — intervention group
Group type: EXPERIMENTAL
Intervention: Discontinuation of ACEIs and ARBs on the day of surgery
Number of subjects: 644
Study 24681657 — intervention group
Group type: COMPARATOR
Intervention: Continuation of ACEIs and ARBs on the day of surgery
Number of subjects: 644
Study 24681657 — intervention group
Group type: EXPERIMENTAL
Intervention: Discontinuation of ACEIs and ARBs
Number of subjects: 644
Study 24681657 — intervention group
Group type: COMPARATOR
Intervention: Continuation of ACEIs and ARBs
Number of subjects: 644
Study 22691900 — intervention group
Group type: EXPERIMENTAL
Intervention: Olmesartan medoxomil (OM) 20 mg (weeks 1-4), 40 mg (weeks 5-8)
Number of subjects: 0
Study 22691900 — intervention group
Group type: COMPARATOR
Intervention: Losartan potassium (LOS) 50 mg (weeks 1-4), 100 mg (weeks 5-8)
Number of subjects: 0
Study 22691900 — intervention group
Group type: EXPERIMENTAL
Intervention: Olmesartan medoxomil (OM)
Number of subjects: 0
Study 22691900 — intervention group
Group type: COMPARATOR
Intervention: Losartan potassium (LOS)
Number of subjects: 0
Study 18385188 — intervention group
Group type: EXPERIMENTAL
Intervention: Headgear
Number of subjects: 82
Study 18535277 — intervention group
Group type: EXPERIMENTAL
Intervention: Contrast-enhanced transcranial Doppler during normal breathing in recumbent position
Number of subjects: 109
Study 18535277 — intervention group
Group type: EXPERIMENTAL
Intervention: Contrast-enhanced transcranial Doppler during normal breathing in standing position
Number of subjects: 109
Study 18535277 — intervention group
Group type: EXPERIMENTAL
Intervention: Contrast-enhanced transcranial Doppler after Valsalva maneuver in recumbent position
Number of subjects: 109
Study 18535277 — intervention group
Group type: EXPERIMENTAL
Intervention: Contrast-enhanced transcranial Doppler after Valsalva maneuver in standing position
Number of subjects: 109
Study 18535277 — intervention group
Group type: EXPERIMENTAL
Intervention: Postural dependency of right to left shunt
Number of subjects: 109
Study 15246631 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV11 L1 VLP vaccine (10 microg)
Number of subjects: 0
Study 15246631 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV11 L1 VLP vaccine (20 microg)
Number of subjects: 0
Study 15246631 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV11 L1 VLP vaccine (50 microg)
Number of subjects: 0
Study 15246631 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV11 L1 VLP vaccine (100 microg)
Number of subjects: 0
Study 15246631 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV16 L1 VLP vaccine (10 microg)
Number of subjects: 0
Study 15246631 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV16 L1 VLP vaccine (40 microg)
Number of subjects: 0
Study 15246631 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV16 L1 VLP vaccine (80 microg)
Number of subjects: 0
Study 15246631 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 11157430 — intervention group
Group type: EXPERIMENTAL
Intervention: Case management
Number of subjects: 708
Study 11157430 — intervention group
Group type: COMPARATOR
Intervention: Control group (British Whites)
Number of subjects: 708
Study 9304946 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteroclysis therapy
Number of subjects: 300
Study 8392360 — intervention group
Group type: EXPERIMENTAL
Intervention: Terbutaline 7.5 mg, administered twice daily for 1 week
Number of subjects: 15
Study 8392360 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol 80 mg, administered twice daily for 1 week
Number of subjects: 15
Study 8392360 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 3511328 — intervention group
Group type: EXPERIMENTAL
Intervention: Bubble oxygenator
Number of subjects: 91
Study 3511328 — intervention group
Group type: COMPARATOR
Intervention: Bubble oxygenator with methylprednisolone sodium succinate (30 mg/kg)
Number of subjects: 91
Study 3511328 — intervention group
Group type: COMPARATOR
Intervention: Membrane oxygenator
Number of subjects: 91
Study 28558709 — intervention group
Group type: EXPERIMENTAL
Intervention: Unconditional cash transfers
Number of subjects: 300
Study 28558709 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 300
Study 27156829 — intervention group
Group type: EXPERIMENTAL
Intervention: Early discharge (within 48 to 56 hours)
Number of subjects: 769
Study 27156829 — intervention group
Group type: COMPARATOR
Intervention: Standard discharge (longer than 56 hours)
Number of subjects: 769
Study 27156829 — intervention group
Group type: EXPERIMENTAL
Intervention: Early discharge
Number of subjects: 769
Study 27156829 — intervention group
Group type: COMPARATOR
Intervention: Standard discharge
Number of subjects: 769
Study 25059500 — intervention group
Group type: EXPERIMENTAL
Intervention: Sit-stand workstation (Ergotron Workfit S) for four weeks
Number of subjects: 42
Study 21887679 — intervention group
Group type: EXPERIMENTAL
Intervention: Ezatiostat
Number of subjects: 89
Study 19150417 — intervention group
Group type: EXPERIMENTAL
Intervention: Single breath measurement (TLCSB)
Number of subjects: 55
Study 19150417 — intervention group
Group type: EXPERIMENTAL
Intervention: Rebreathe helium dilution (TLCRB)
Number of subjects: 55